{"title":"心脏再同步化治疗伴或不伴除颤","authors":"M. Akbarzadeh, A. Salehi","doi":"10.21859/IJCP-03031","DOIUrl":null,"url":null,"abstract":"Indications for cardiac resynchronization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) was challenging in the early 2000s. There were many researches to and fro of CRT-D versus CRT-P implantation in patients with cardiomyopathy (CMP) and left bundle branch block pattern in electrocardiography. In 2012, ACC/AHA/HRS (American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society) guidelines, recommendations for implantable cardioverter defibrillator (ICD), was completely apart to the indications of CRT[1]. In such guidelines, ICD indicated for most of patients with ischemic CMP and patients with non-ischemic CMP with high functional class. Therefore, ICD simultaneously indicated many patients benefitting from CRT. Therefore, the indications for CRT-P are very limited according to these guidelines [1]. The ESC guideline recommends implantation of CRT-P instead of CRT-D only in patients with short life expectancy such as the ones with advanced renal failure [2]. Although left ventricular ejection fraction (LVEF) is an excellent practical marker of ventricular arrhythmic events, however, only a small percentage of ICD recipients receive appropriate ICD therapy [3]. The predictors of appropriate ICD therapy markedly vary between the studies. Non-sustained ventricular tachycardia, abnormal sphericity index, male gender, high NYHA (New York Heart Association) functional class, and smoking were reported as predictors for ventricular arrhythmia in few studies, but still not approved as good markers to change the decision [4-6]. Recently, the benefit of ICD for patients with dilated CMP was doubted in a Danish trial. This trial demonstrated that ICD implantation did not have survival benefits for patients with symptomatic heart failure not caused by coronary artery disease [7]. Accordingly, a recent study showed that midwall fibrosis detected by magnetic resonance imaging (MRI) may be a good predictor for adverse outcomes including ventricular tachyarrhythmia and sudden arrhythmic death in the patients with non-ischemic CMP; hence, CRT-D may be superior to CRT-P in this subgroup of patients with non-ischemic CMP [8]. On the other hand, in many pacemaker-dependent patients, only RV pacing may cause CMP. Kiehl et al., showed that incidence of pacemaker-induced cardiomyopathy was about 12.3% in patients with complete heart block treated with pacemaker; hence, it may be necessary to upgrade their device to CRT [9]. According to the current AHA and ESC guidelines, CRT implantation or upgrading to CRT device is observed in patients with high ventricular pacing and Cardiac Resynchronization Therapy With or Without Defibrillation","PeriodicalId":31436,"journal":{"name":"International Journal of Cardiovascular Practice","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Cardiac Resynchronization Therapy With or Without Defibrillation\",\"authors\":\"M. Akbarzadeh, A. Salehi\",\"doi\":\"10.21859/IJCP-03031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Indications for cardiac resynchronization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) was challenging in the early 2000s. There were many researches to and fro of CRT-D versus CRT-P implantation in patients with cardiomyopathy (CMP) and left bundle branch block pattern in electrocardiography. In 2012, ACC/AHA/HRS (American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society) guidelines, recommendations for implantable cardioverter defibrillator (ICD), was completely apart to the indications of CRT[1]. In such guidelines, ICD indicated for most of patients with ischemic CMP and patients with non-ischemic CMP with high functional class. Therefore, ICD simultaneously indicated many patients benefitting from CRT. Therefore, the indications for CRT-P are very limited according to these guidelines [1]. The ESC guideline recommends implantation of CRT-P instead of CRT-D only in patients with short life expectancy such as the ones with advanced renal failure [2]. Although left ventricular ejection fraction (LVEF) is an excellent practical marker of ventricular arrhythmic events, however, only a small percentage of ICD recipients receive appropriate ICD therapy [3]. The predictors of appropriate ICD therapy markedly vary between the studies. Non-sustained ventricular tachycardia, abnormal sphericity index, male gender, high NYHA (New York Heart Association) functional class, and smoking were reported as predictors for ventricular arrhythmia in few studies, but still not approved as good markers to change the decision [4-6]. Recently, the benefit of ICD for patients with dilated CMP was doubted in a Danish trial. This trial demonstrated that ICD implantation did not have survival benefits for patients with symptomatic heart failure not caused by coronary artery disease [7]. Accordingly, a recent study showed that midwall fibrosis detected by magnetic resonance imaging (MRI) may be a good predictor for adverse outcomes including ventricular tachyarrhythmia and sudden arrhythmic death in the patients with non-ischemic CMP; hence, CRT-D may be superior to CRT-P in this subgroup of patients with non-ischemic CMP [8]. On the other hand, in many pacemaker-dependent patients, only RV pacing may cause CMP. Kiehl et al., showed that incidence of pacemaker-induced cardiomyopathy was about 12.3% in patients with complete heart block treated with pacemaker; hence, it may be necessary to upgrade their device to CRT [9]. According to the current AHA and ESC guidelines, CRT implantation or upgrading to CRT device is observed in patients with high ventricular pacing and Cardiac Resynchronization Therapy With or Without Defibrillation\",\"PeriodicalId\":31436,\"journal\":{\"name\":\"International Journal of Cardiovascular Practice\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cardiovascular Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21859/IJCP-03031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiovascular Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21859/IJCP-03031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
在21世纪初,心脏再同步化治疗(CRT)与除颤(CRT- d)相比起搏(CRT- p)的适应症具有挑战性。在心肌病(CMP)患者中,CRT-D与CRT-P植入以及心电图左束支阻滞模式的研究有很多。2012年,ACC/AHA/HRS (American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and Heart Rhythm Society)指南推荐植入式心律转复除颤器(ICD)与CRT的适应症完全分开[1]。在该指南中,ICD适用于大多数缺血性CMP患者和高功能分级的非缺血性CMP患者。因此,ICD同时显示许多患者受益于CRT。因此,根据这些指南,CRT-P的适应症非常有限[1]。ESC指南建议仅在预期寿命较短的患者(如晚期肾衰竭患者)中植入CRT-P而不是CRT-D[2]。尽管左室射血分数(left ventricular ejection fraction, LVEF)是室性心律失常事件的一个极好的实用指标,然而,只有一小部分ICD受者接受了适当的ICD治疗[3]。适当的ICD治疗的预测因素在研究之间显著不同。在少数研究中,非持续性室性心动过速、球形指数异常、男性、NYHA(纽约心脏协会)功能等级高和吸烟被报道为室性心律失常的预测因素,但仍未被批准为改变决策的良好标志[4-6]。最近,在丹麦的一项试验中,ICD对扩张型CMP患者的益处受到质疑。该试验表明,对于非冠状动脉疾病引起的症状性心力衰竭患者,ICD植入没有生存获益[7]。因此,最近的一项研究表明,通过磁共振成像(MRI)检测到的中壁纤维化可能是非缺血性CMP患者不良后果的良好预测指标,包括室性心动过速和突发性心律失常死亡;因此,在该亚组非缺血性CMP患者中,CRT-D可能优于CRT-P[8]。另一方面,在许多依赖起搏器的患者中,只有右心室起搏可能导致CMP。Kiehl等人的研究表明,在接受起搏器治疗的完全性心脏传导阻滞患者中,起搏器诱发的心肌病发生率约为12.3%;因此,可能需要将其设备升级为CRT[9]。根据目前的AHA和ESC指南,在高心室起搏和心脏再同步化治疗伴或不伴除颤的患者中观察到CRT植入或升级到CRT装置
Cardiac Resynchronization Therapy With or Without Defibrillation
Indications for cardiac resynchronization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) was challenging in the early 2000s. There were many researches to and fro of CRT-D versus CRT-P implantation in patients with cardiomyopathy (CMP) and left bundle branch block pattern in electrocardiography. In 2012, ACC/AHA/HRS (American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society) guidelines, recommendations for implantable cardioverter defibrillator (ICD), was completely apart to the indications of CRT[1]. In such guidelines, ICD indicated for most of patients with ischemic CMP and patients with non-ischemic CMP with high functional class. Therefore, ICD simultaneously indicated many patients benefitting from CRT. Therefore, the indications for CRT-P are very limited according to these guidelines [1]. The ESC guideline recommends implantation of CRT-P instead of CRT-D only in patients with short life expectancy such as the ones with advanced renal failure [2]. Although left ventricular ejection fraction (LVEF) is an excellent practical marker of ventricular arrhythmic events, however, only a small percentage of ICD recipients receive appropriate ICD therapy [3]. The predictors of appropriate ICD therapy markedly vary between the studies. Non-sustained ventricular tachycardia, abnormal sphericity index, male gender, high NYHA (New York Heart Association) functional class, and smoking were reported as predictors for ventricular arrhythmia in few studies, but still not approved as good markers to change the decision [4-6]. Recently, the benefit of ICD for patients with dilated CMP was doubted in a Danish trial. This trial demonstrated that ICD implantation did not have survival benefits for patients with symptomatic heart failure not caused by coronary artery disease [7]. Accordingly, a recent study showed that midwall fibrosis detected by magnetic resonance imaging (MRI) may be a good predictor for adverse outcomes including ventricular tachyarrhythmia and sudden arrhythmic death in the patients with non-ischemic CMP; hence, CRT-D may be superior to CRT-P in this subgroup of patients with non-ischemic CMP [8]. On the other hand, in many pacemaker-dependent patients, only RV pacing may cause CMP. Kiehl et al., showed that incidence of pacemaker-induced cardiomyopathy was about 12.3% in patients with complete heart block treated with pacemaker; hence, it may be necessary to upgrade their device to CRT [9]. According to the current AHA and ESC guidelines, CRT implantation or upgrading to CRT device is observed in patients with high ventricular pacing and Cardiac Resynchronization Therapy With or Without Defibrillation